Read articles from Global

June 01, 2026 by clivebates.com

Global tobacco policy has become increasingly disconnected from the main cause of tobacco-related disease: smoking itself. Safer nicotine products such as vapes, nicotine pouches and heated tobacco products are presented as part of the solution, yet many health authorities continue to treat them as a threat rather than an opportunity for harm reduction. Misleading statistics, particularly around youth vaping, can encourage policies that fail to reduce smoking and may unintentionally push people back towards cigarettes. Strong restrictions and bans risk expanding illicit markets while making safer alternatives harder for adults who smoke to access. A more effective approach would be evidence-based, risk-proportionate regulation that recognises the significant differences between combustible cigarettes and smoke-free nicotine products.

June 01, 2026 by clivebates.com

Global tobacco policy has become increasingly disconnected from the main cause of tobacco-related disease: smoking itself. Safer nicotine products such as vapes, nicotine pouches and heated tobacco products are presented as part of the solution, yet many health authorities continue to treat them as a threat rather than an opportunity for harm reduction. Misleading statistics, particularly around youth vaping, can encourage policies that fail to reduce smoking and may unintentionally push people back towards cigarettes. Strong restrictions and bans risk expanding illicit markets while making safer alternatives harder for adults who smoke to access. A more effective approach would be evidence-based, risk-proportionate regulation that recognises the significant differences between combustible cigarettes and smoke-free nicotine products.

June 01, 2026 by gfn.tv

Restrictions on safer nicotine products are framed as a threat to individual freedom as well as a public health concern. Policies driven by fear rather than evidence can make it harder for adults who smoke to access less harmful alternatives. Bans, high taxes and strict regulations may also strengthen illicit markets, leaving consumers with fewer safe and legal options. The piece challenges the idea that prohibition protects the public, arguing that it often creates new risks while ignoring personal responsibility. A more balanced approach would recognise adult choice, reduce harm and avoid treating all nicotine use as a moral failure.

May 29, 2026 by substack.com

World No Tobacco Day is renewing debate over whether global tobacco control should focus more on engagement with smokers rather than exclusion or stigma. Harm reduction advocates argue that people who smoke are more likely to benefit from accurate information, practical support and access to lower-risk alternatives than from shame-based messaging. The discussion highlights concerns that abstinence-only approaches may overlook the behavioural realities of nicotine dependence and the needs of smokers who have not quit through conventional methods. A more inclusive public health strategy would prioritise empathy, risk reduction and evidence-based pathways away from combustible tobacco.

May 29, 2026 by substack.com

Risk analysis of nicotine and tobacco products requires a clear distinction between combustible smoke exposure and non-combustible forms of nicotine delivery. Evidence on cancer and non-cancer risks continues to show that the greatest health burden is linked to toxicants produced through combustion, rather than nicotine itself. Researchers argue that comparing products through relative risk, exposure levels and disease pathways is essential for avoiding misleading conclusions in public health communication. The analysis reinforces the importance of evidence-based regulation that recognises meaningful differences between cigarettes, vaping products and other smoke-free nicotine alternatives.

May 27, 2026 by regulatorwatch.com

Longstanding public health narratives around nicotine are facing renewed scrutiny as tobacco harm reduction challenges older assumptions shaped by the cigarette era. Critics argue that framing nicotine itself as the central danger has contributed to public misunderstanding of reduced-risk products such as vapes, where the main issue is not combustion but the delivery of nicotine without smoke. The discussion raises concerns that fear-based language, including terms such as “epidemic” and misleading comparisons with illicit drugs, may distort risk perception and weaken evidence-based policy. Broader questions remain over whether tobacco control can adapt to scientific evidence on relative risk while maintaining credible public health communication.

May 27, 2026 by regulatorwatch.com

Longstanding public health narratives around nicotine are facing renewed scrutiny as tobacco harm reduction challenges older assumptions shaped by the cigarette era. Critics argue that framing nicotine itself as the central danger has contributed to public misunderstanding of reduced-risk products such as vapes, where the main issue is not combustion but the delivery of nicotine without smoke. The discussion raises concerns that fear-based language, including terms such as “epidemic” and misleading comparisons with illicit drugs, may distort risk perception and weaken evidence-based policy. Broader questions remain over whether tobacco control can adapt to scientific evidence on relative risk while maintaining credible public health communication.

May 27, 2026 by regulatorwatch.com

Longstanding public health narratives around nicotine are facing renewed scrutiny as tobacco harm reduction challenges older assumptions shaped by the cigarette era. Critics argue that framing nicotine itself as the central danger has contributed to public misunderstanding of reduced-risk products such as vapes, where the main issue is not combustion but the delivery of nicotine without smoke. The discussion raises concerns that fear-based language, including terms such as “epidemic” and misleading comparisons with illicit drugs, may distort risk perception and weaken evidence-based policy. Broader questions remain over whether tobacco control can adapt to scientific evidence on relative risk while maintaining credible public health communication.

May 26, 2026 by planetofthevapes.co.uk

Criticism of the WHO’s tobacco control strategy is increasingly centred on concerns that global policy is failing to recognise evidence from countries that have reduced smoking through harm reduction approaches. Advocates argue that lower-risk nicotine products, including vapes, snus and nicotine pouches, can play an important role in reducing exposure to the harms caused by combustible tobacco. The debate highlights ongoing tensions between abstinence-focused regulation and policies based on relative risk, consumer behaviour and real-world public health outcomes. Questions continue to grow over whether international tobacco control frameworks are adapting quickly enough to innovation, scientific evidence and declining smoking rates in countries that have embraced safer alternatives.

May 26, 2026 by marijuanamoment.net

Clinical research into psilocybin-assisted therapy is adding to growing interest in psychedelic compounds as potential treatments for depression. A recent randomised trial found that a single dose of psilocybin, combined with psychotherapy, was associated with rapid improvements in depressive symptoms, with some effects lasting for several months. Researchers note, however, that the long-term benefits remain uncertain and that repeated or maintenance treatment may be needed to prevent relapse. The findings contribute to broader scientific debate over how psychedelic therapies should be studied, regulated, and integrated into mental health care.